Penumbra PEN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Thrombectomy | $975.29M+14.2% | $947.92M+16.2% | $913.35M+16.2% | $881.07M+15.8% | $854.32M+18.6% | |
| Revenue by Geography | ||||||
| United States | $1.13B+19.2% | $1.09B+21.0% | $1.04B+21.3% | $991.92M+20.0% | $949.28M+19.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Penumbra break its business down?
- Penumbra (PEN) reports revenue by product across 3 parts — Embolization and Access, Embolization and Other and Thrombectomy. Each is extracted from the segment footnotes and tracked over time.
- Where does Penumbra's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Penumbra's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
